Heparanase and hepatocellular carcinoma: Promoter or inhibitor?

doi:10.3748/wjg.v16.i3.306

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4029)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

275

HTML

3456

Figures (1-1)

153

Tables (1-1)

145

Sum=4029

Jan 21, 2010 (publication date) through Jun 5, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 21, 2010; 16(3): 306-311
Published online Jan 21, 2010. doi: 10.3748/wjg.v16.i3.306

Open in New Tab Full Size Figure Download Figure

Figure 1 Heparan sulphate proteoglycan (HSPG) and fibroblast growth factor (FGF)-induced signal transduction. Basic FGF (bFGF) enhances tumor progression by protecting tumor cells from apoptosis. Cell surface HSPGs could act as a co-receptor for formation of a bFGF high-affinity receptor complex. The alteration of cell surface HSPGs resulting from heparanase might down-regulate HSPG-mediated bFGF-induced signal pathway, resulting in apoptosis of tumor cells.

Citation: Dong S, Wu XZ. Heparanase and hepatocellular carcinoma: Promoter or inhibitor? World J Gastroenterol 2010; 16(3): 306-311
URL: https://www.wjgnet.com/1007-9327/full/v16/i3/306.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i3.306